文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

放疗后复发前列腺癌的挽救性近距离治疗:uroGEC专家背书综述

Salvage brachytherapy for recurrent prostate cancer after radiotherapy: An expert-endorsed review by uroGEC.
PubMed 文献 · Radiother Oncol · 2025-07-08

该叙述性综述由uroGEC背书,总结挽救性近距离治疗(LDR或HDR)用于原发性放疗后局部复发前列腺癌的适应证、技术、结局与局限。患者选择需基于严格再分期(多参数MRI和/或PSMA PET)及组织学确认;5年生化控制率报告为50-70%,泌尿生殖与胃肠道毒性可接受。证据受限于小样本异质性队列及缺乏前瞻性随机试验。

要点

  • 挽救性近距离治疗适用于严格选择的放疗后局部复发前列腺癌患者。
  • 再分期需多参数MRI和/或PSMA PET,并组织学确认局部复发。
  • 5年生化控制率报告为50-70%,现代影像与技术下毒性可接受。

核心结论

  • 挽救性近距离治疗是严格选择局部复发前列腺癌患者的有价值选择,应纳入个体化影像引导治疗策略。

研究设计与样本

  • 由uroGEC背书的叙述性综述,总结挽救性近距离治疗用于原发性放疗后局部复发前列腺癌的当前证据、适应证、技术、结局与局限。

主要发现

  • 报告5年生化控制率范围为50-70%,泌尿生殖与胃肠道毒性可接受,尤其在使用先进影像和现代近距离治疗技术时。
  • 影像引导的局部病灶近距离治疗仅靶向复发灶,已成为全腺体再照射的可行且毒性更低的替代方案。

关键数值与推荐

  • 患者选择应基于严格再分期,包括多参数MRI和/或PSMA PET,以及局部复发的组织学确认。
  • uroGEC专家小组倡导多学科决策、标准化方案及将患者纳入临床试验。

临床怎么用

  • 对严格选择的放疗后局部复发患者,可考虑LDR或HDR挽救性近距离治疗,包括影像引导的局部病灶治疗。
  • 治疗决策应多学科进行,并采用标准化方案,同时鼓励患者参与临床试验。

局限性

  • 证据受限于小型、异质性队列,且缺乏前瞻性随机试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiorecurrent prostate cancer remains a challenging clinical scenario. Salvage brachytherapy, either low-dose-rate (LDR) or high-dose-rate (HDR), offers a promising organ-preserving option in carefully selected patients. This narrative review, endorsed by the uroGEC (Urology - Groupe Européen de Curiethérapie), summarizes current evidence, indications, techniques, outcomes, and limitations of SBT in men with local recurrence after primary radiotherapy. Patient selection is critical and should be based on rigorous restaging, including multiparametric MRI and/or PSMA PET, as well as histological confirmation of local recurrence. Focal BT, guided by imaging and targeting only the recurrent lesion, has emerged as a feasible and less toxic alternative to whole-gland re-irradiation. Reported biochemical control rates range between 50-70 % at 5 years, with acceptable genitourinary and gastrointestinal toxicity profiles, particularly when advanced imaging and modern brachytherapy techniques are used. Despite promising results, the evidence remains limited by small, heterogeneous cohorts and lack of prospective randomized trials. The uroGEC expert panel advocates for multidisciplinary decision-making, standardized protocols, and patient inclusion in clinical trials to better define the role of BT. In conclusion, BT represents a valuable salvage option in well-selected patients with localized recurrence, and should be considered in the context of individualized, image-guided treatment strategies.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gomez-Iturriaga A, Tselis N, Willisch P, et al. Salvage brachytherapy for recurrent prostate cancer after radiotherapy: An expert-endorsed review by uroGEC. Radiother Oncol. 2025. PMID: 40639765. doi:10.1016/j.radonc.2025.111042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。